Alterity Therapeutics
ATHE
11 hedge funds and large institutions have $1.48M invested in Alterity Therapeutics in 2020 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 0 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
17% more capital invested
Capital invested by funds: $1.27M → $1.48M (+$218K)
10% more funds holding
Funds holding: 10 → 11 (+1)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$293K |
| 2 |
Renaissance Technologies
New York
|
+$251K |
| 3 |
Morgan Stanley
New York
|
+$214K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.65K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$221 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
-$3.15K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $780K | +$214K | +13,612 | +31% |
|
|
2
Renaissance Technologies
New York
| $431K | +$251K | +15,928 | +98% |
|
|
SM
3
Sabby Management
Miami Beach,
Florida
| $249K | +$293K | +18,584 | New |
|
4
Geode Capital Management
Boston,
Massachusetts
| $16K | – | – | – |
|
5
Wells Fargo
San Francisco,
California
| $3K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $3K | +$2.65K | +168 | +700% |
|
|
GWM
7
Geneos Wealth Management
Englewood,
Colorado
| $1K | -$3.15K | -200 | -63% |
|
|
APA
8
American Portfolios Advisors
Holbrook,
New York
| $111 | – | – | – |
|
|
9
Osaic Holdings
Scottsdale,
Arizona
| – | +$221 | +14 | +58% |
|
ATHE Hedge Fund Activity: Q4 2020 in Review
11 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q4 2020, worth a combined $1.48M — up 17% from $1.27M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ATHE positions and 0 closed out — a net gain of 1 holder — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $293K. The largest seller was Geneos Wealth Management, cutting an estimated $3.15K.
- 11 institutional investors held Alterity Therapeutics (ATHE) as of Q4 2020, up from 10 in Q3 2020.
- Funds reported $1.48M of Alterity Therapeutics stock for Q4 2020, up 17% quarter-over-quarter.
- 1 fund opened new Alterity Therapeutics positions in Q4 2020 and 0 closed out, a net change of +1 holder.
- The largest Alterity Therapeutics buyer in Q4 2020 was Sabby Management, an estimated $293K added.
- The largest Alterity Therapeutics seller in Q4 2020 was Geneos Wealth Management, an estimated $3.15K sold.
Based on aggregated 13F filings for Q4 2020.